FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2406704015> ?p ?o ?g. }

• W2406704015 endingPage "B143" @default.
• W2406704015 startingPage "B143" @default.
• W2406704015 abstract "Abstract Introduction: Tumor-associated macrophages (TAMs) are a major cellular component of human tumors, and actively suppress anti-tumor immune responses. Colony stimulating factor 1 receptor (CSF1R) signaling plays a major role in the differentiation and survival of TAMs. Programmed cell death 1 (PD-1) is expressed on exhausted lymphocytes in the tumor, and delivers a negative signal to suppress lymphocyte activation. FPA008 is a humanized IgG4 monoclonal antibody that binds to human CSF1R, and blocks the ability of IL34 and CSF1 to activate CSF1R expressed on macrophages. Nivolumab is a fully-human lgG4 PD-1 immune checkpoint inhibitor that blocks the interaction of PD-1 with its ligands (PD-L1 and PD-L2), thereby inhibiting the negative signal and promoting the host immune response. This immune response can then recognize and eliminate tumor cells. Blocking CSF1R with FPA008 treatment could alleviate the immunosuppressive tumor environment that is generated by TAMs and create an environment that is more conducive to immune-based anti-cancer therapies such as nivolumab. Experimental Procedures: This open-label study is designed to evaluate the safety of FPA008 alone and in combination with nivolumab. Eligible patients (≥ 18 years) with advanced cancers will have an Eastern Cooperative Oncology Group performance status of 0 or 1. The Phase 1a dose escalation will include all advanced solid tumors and the Phase 1b expansion part of this study will focus on six tumor types: non-small cell lung cancer, melanoma, head and neck cancer, pancreatic cancer, colorectal cancer, and malignant glioma. For Phase 1a, the primary objectives are to assess the safety and tolerability of FPA008 alone and in combination with 3 mg/kg nivolumab, and to determine the maximum tolerated dose of FPA008 in this combination. Secondary objectives include an assessment of pharmacokinetics, objective response rate, overall survival, duration of response, and progression-free survival of FPA008 in combination with nivolumab. Pre- and on-treatment biopsies will be collected from patients to characterize the tumor microenvironment and examine pharmacodynamic responses to treatment. Additionally, post-progression biopsies in a subset of patients will be collected to study potential mechanisms of resistance. Exploratory objectives for Phase 1a and Phase 1b include an evaluation of biomarkers and their relationship to tumor response. Summary: This is a Phase 1 study designed in two parts to assess the safety and tolerability of FPA008 alone and in combination with nivolumab. This study will also assess efficacy and correlate response with pharmacodynamic markers of activity for both drugs. Conclusions: Emerging data elucidate the contribution TAMs make to immunosuppression in the tumor microenvironment. Inhibition of TAMs by FPA008 may reduce their immunosuppressive effects and increase T cell anti-tumor responses. This activity may be further enhanced by combining FPA008 with a PD-1 inhibitor, such as nivolumab. This study will evaluate the safety and preliminary efficacy of this novel combination in treating patients with advanced cancers. (NCT Number pending) Citation Format: Julie Brahmer, Drew Rasco, Minjia Chen, Emma Masteller, Ibrahim Qazi, Seema Rogers, Neil Sankar, Robert Sikorski, Julie Hambleton, F. Stephen Hodi. A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr B143." @default.
• W2406704015 created "2016-06-24" @default.
• W2406704015 creator A5000095180 @default.
• W2406704015 creator A5016263949 @default.
• W2406704015 creator A5018401879 @default.
• W2406704015 creator A5045047962 @default.
• W2406704015 creator A5050440486 @default.
• W2406704015 creator A5059403541 @default.
• W2406704015 creator A5061049869 @default.
• W2406704015 creator A5073134832 @default.
• W2406704015 creator A5084967339 @default.
• W2406704015 creator A5085763881 @default.
• W2406704015 date "2016-01-01" @default.
• W2406704015 modified "2023-09-26" @default.
• W2406704015 title "Abstract B143: A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers" @default.
• W2406704015 doi "https://doi.org/10.1158/2326-6074.cricimteatiaacr15-b143" @default.
• W2406704015 hasPublicationYear "2016" @default.
• W2406704015 type Work @default.
• W2406704015 sameAs 2406704015 @default.
• W2406704015 citedByCount "7" @default.
• W2406704015 countsByYear W24067040152017 @default.
• W2406704015 countsByYear W24067040152019 @default.
• W2406704015 countsByYear W24067040152021 @default.
• W2406704015 countsByYear W24067040152022 @default.
• W2406704015 crossrefType "journal-article" @default.
• W2406704015 hasAuthorship W2406704015A5000095180 @default.
• W2406704015 hasAuthorship W2406704015A5016263949 @default.
• W2406704015 hasAuthorship W2406704015A5018401879 @default.
• W2406704015 hasAuthorship W2406704015A5045047962 @default.
• W2406704015 hasAuthorship W2406704015A5050440486 @default.
• W2406704015 hasAuthorship W2406704015A5059403541 @default.
• W2406704015 hasAuthorship W2406704015A5061049869 @default.
• W2406704015 hasAuthorship W2406704015A5073134832 @default.
• W2406704015 hasAuthorship W2406704015A5084967339 @default.
• W2406704015 hasAuthorship W2406704015A5085763881 @default.
• W2406704015 hasConcept C121608353 @default.
• W2406704015 hasConcept C126322002 @default.
• W2406704015 hasConcept C143998085 @default.
• W2406704015 hasConcept C159654299 @default.
• W2406704015 hasConcept C203014093 @default.
• W2406704015 hasConcept C2777658100 @default.
• W2406704015 hasConcept C2777701055 @default.
• W2406704015 hasConcept C2780030458 @default.
• W2406704015 hasConcept C2780674031 @default.
• W2406704015 hasConcept C2780851360 @default.
• W2406704015 hasConcept C502942594 @default.
• W2406704015 hasConcept C542903549 @default.
• W2406704015 hasConcept C71924100 @default.
• W2406704015 hasConcept C8891405 @default.
• W2406704015 hasConceptScore W2406704015C121608353 @default.
• W2406704015 hasConceptScore W2406704015C126322002 @default.
• W2406704015 hasConceptScore W2406704015C143998085 @default.
• W2406704015 hasConceptScore W2406704015C159654299 @default.
• W2406704015 hasConceptScore W2406704015C203014093 @default.
• W2406704015 hasConceptScore W2406704015C2777658100 @default.
• W2406704015 hasConceptScore W2406704015C2777701055 @default.
• W2406704015 hasConceptScore W2406704015C2780030458 @default.
• W2406704015 hasConceptScore W2406704015C2780674031 @default.
• W2406704015 hasConceptScore W2406704015C2780851360 @default.
• W2406704015 hasConceptScore W2406704015C502942594 @default.
• W2406704015 hasConceptScore W2406704015C542903549 @default.
• W2406704015 hasConceptScore W2406704015C71924100 @default.
• W2406704015 hasConceptScore W2406704015C8891405 @default.
• W2406704015 hasIssue "1_Supplement" @default.
• W2406704015 hasLocation W24067040151 @default.
• W2406704015 hasOpenAccess W2406704015 @default.
• W2406704015 hasPrimaryLocation W24067040151 @default.
• W2406704015 hasRelatedWork W1963731933 @default.
• W2406704015 hasRelatedWork W2292951650 @default.
• W2406704015 hasRelatedWork W2886039816 @default.
• W2406704015 hasRelatedWork W2984962695 @default.
• W2406704015 hasRelatedWork W3217412908 @default.
• W2406704015 hasRelatedWork W4206362823 @default.
• W2406704015 hasRelatedWork W4281723870 @default.
• W2406704015 hasRelatedWork W4304783156 @default.
• W2406704015 hasRelatedWork W4315631827 @default.
• W2406704015 hasRelatedWork W4360983034 @default.
• W2406704015 hasVolume "4" @default.
• W2406704015 isParatext "false" @default.
• W2406704015 isRetracted "false" @default.
• W2406704015 magId "2406704015" @default.
• W2406704015 workType "article" @default.